Clinical Endocrinology · 2007 · 31 citations · 27 references
Life SciencesGeneticsMolecular GeneticsDna RepairGenetic EpidemiologyMedical GeneticsGenetic Risk AssessmentGenetic Risk FactorsGenetic SusceptibilityGenotype-phenotype Association AnalysisGenotype-phenotype CorrelationMolecular Risk FactorsCytochrome P450 Genetic PolymorphismDna Damage Response GenesGenetic PolymorphismsGermline Genetic PolymorphismsSingle Nucleotide Polymorphism Association StudiesSingle-nucleotide Polymorphism Risk Analysis
OBJECTIVE: Cigarette smoking is a well-recognized risk factor of Graves' disease and, particularly, Graves' ophthalmopathy. Hence, germline polymorphisms of detoxification genes and genes belonging to the major DNA repair-apoptosis pathways might have an important role in disease susceptibility. In addition, as some of these genes are regulated by thyroid hormones, they may affect the patients' outcomes. We aimed to assess the influence of the GST, CYP and TP53 gene polymorphisms in the risk of Graves' disease and its outcome. DESIGN: Prospective case-control study. PATIENTS: A PCR-based strategy was used for GSTT1, GSTM1, GSTP1, CYP1A1 and TP53 codon 72 genotypes in a group of 400 Graves' disease patients, and to compare them to 574 control individuals with similar environmental exposure features. RESULTS: GSTM1 and GSTT1 genotypes were equally distributed in cases and controls, respectively. However, GSTP1 (P < 0.0001), CYP1A1 (P < 0.0033) and Pro/ProTP53 (P < 0.0035) variants appeared more frequently in Graves' disease patients than in controls. A multivariate analysis indicated that cigarette smoking and inheritance of GSTP1, CYP1A1 and Pro/ProTP53 variants were important risk factors for Graves' disease, but only smoking appeared as an independent risk factor for Graves' ophthalmopathy. There was no association between clinical features, including ophthalmopathy or treatment outcome, and the studied genotypes. CONCLUSION: We concluded that GSTP1, CYP1A1 and TP53, but not GSTT1 and GSTM1 germline polymorphisms, may be associated with smoking-related Graves' disease susceptibility and configure a risk profile for the disease. However, these polymorphisms do not influence the patients' response to treatment.
27
Thomas Heiberg Brix, Kirsten Ohm Kyvik, Kaare Christensen et al. · The Journal of Clinical Endocrinology & Metabolism · 2001 · 409 citations · Full text
Cell Suicide in Health and Disease
Richard C. Duke, David M. Ojcius, John Ding‐E Young · Scientific American · 1996 · 216 citations